Blood pressure, antihypertensive treatment and factors associated with good blood pressure control in hypertensive diabetics:: the Tarmidas study

被引:7
作者
de Pablos-Velasco, P. [1 ]
Gonzalez-Albarran, O.
Estopinan, V.
Khanbhai, A.
机构
[1] Hosp Gen de Gran Canaria Doctor Negrin, Dept Endocrinol, Las Palmas Gran Canaria, Spain
[2] Hosp Ramon & Cajal, Dept Endocrinol, E-28034 Madrid, Spain
[3] Hosp Obispo Polanco, Dept Endocrinol, Teruel, Spain
[4] Abbott Labs, Dept Med, Madrid, Spain
关键词
diabetes; antihypertensive; epidemiological; management; Spain;
D O I
10.1038/sj.jhh.1002214
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Numerous population studies confirm the high prevalence of hypertension in type II diabetic (DM2) subjects and that intensive antihypertensive treatment is more beneficial to diabetic than to nondiabetic hypertensive subjects, yet not many of these are specific to Spain. To assess the degree of blood pressure (BP) control and the effects of antihypertensive drugs in the medical management of hypertension in diabetic patients in specialist care centres throughout Spain, we studied the socio-demographic, clinical and relevant laboratory parameters of 796 hypertensive patients with DM2 ( mean age 66.09 (95% confidence interval (CI): 64.08-68.10). The percentage of diabetic patients responding positively to BP control measures was lower when compared to the nondiabetic population in both Spain and Europe. The degree of control was poorer for systolic than for diastolic BP, yet 40.6% of the patients were only on monotherapy. The fact that antihypertensive treatment was modified in only 40% of the poorly controlled patients was also highly significant and could be attributed to a nonstringent use of clinical guidelines. Among the other differences between well-controlled and poorly controlled patients, we found that well-controlled patients presented with lower levels of cholesterol and triglycerides, a lower prevalence of excess weight/obesity, and a greater prevalence of cardiovascular and/or cerebrovascular disease despite having a greater percentage of patients on antiplatelet therapy. Better application of therapeutic guidelines and the prevention and treatment of compounding factors could improve the response rate to BP control measures in poorly controlled patients.
引用
收藏
页码:664 / 672
页数:9
相关论文
共 50 条
  • [1] ADDLER AL, 2000, BMJ-BRIT MED J, V321, P412
  • [2] Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
  • [3] 2-S
  • [4] PREVENCAT study:: control of cardiovascular risk in primary care
    Alvarez-Sala, LA
    Suárez, C
    Mantilla, T
    Franch, J
    Ruilope, LM
    Banegas, JR
    Barrios, V
    [J]. MEDICINA CLINICA, 2005, 124 (11): : 406 - 410
  • [5] [Anonymous], 2000, Lancet, V355, P253, DOI DOI 10.1016/S0140-6736(99)12323-7
  • [6] Blood pressure control and physician management of hypertension in hospital hypertension units in Spain
    Banegas, JR
    Segura, J
    Ruilope, LM
    Luque, M
    García-Robles, R
    Campo, C
    Rodríguez-Artalejo, F
    Tamargo, J
    [J]. HYPERTENSION, 2004, 43 (06) : 1338 - 1344
  • [7] Birkenhäger WH, 2000, J NEPHROL, V13, P232
  • [8] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [9] Caro JLL, 2004, MED CLIN-BARCELONA, V122, P165
  • [10] Charpentier G, 2002, ARCH MAL COEUR VAISS, V95, P661